FDA Provides Guidance for Adding an Open-Label Extension to CytoDyn’s Phase 3 Trial for Severe-to-Critical COVID-19 Patients Until Trial Data is Unblinded

The agency will also consider eINDs for patients in other hospitals who qualify for inclusion criteria similar to CD12

The CD12 trial completed enrollment with 394 patients on December 16

VANCOUVER, Washington, Dec. 24, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing Vyrologix
(leronlimab-PRO 140), a CCR5